Molecular surveillance of HCV mono-infection and HCV-HBV  co-infection in symptomatic population at Hyderabad, Pakistan

Patoli, Bushra Bano; Patoli, Atif Ahmed; Balani, Nimerta Kumari; Korejo, Ashfaque A

doi:10.4314/ahs.v18i3.9

Cited by 3 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HCV-HBV coinfection can lead to more severe liver disease, increased risk of liver cirrhosis, hepatocellular carcinoma (liver cancer), and a higher mortality rate compared to monoinfection with either virus. 9 Injection drug use, unsafe medical practices (e.g. contaminated needles) and unprotected sexual activity are common risk factors for acquiring both HCV and HBV infections, increasing the likelihood of coinfection.…”

Section: Global Epidemiology Of Hcv-hbv Coinfectionmentioning

confidence: 99%

Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives

Maqsood,

Sumrin,

Iqbal

et al. 2023

Antiviral Therapy

View full text Add to dashboard Cite

In endemic areas, hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfection is common, and patients with coinfection have a higher risk of developing liver disease such as hepatocellular carcinoma, liver fibrosis and cirrhosis. In such cases, HCV predominates, and HBV replication is suppressed by HCV. HCV core proteins and interferons that are activated by HCV are responsible for the suppression of HBV. Immunosuppression is also seen in patients with HCV and HBV coinfections. A decrease in HCV-neutralizing antibody response and circulation of Th1-like Tfh cells is observed in patients with HCV and HBV coinfection. Both viruses interacted in the liver, and treatment of HCV/HBV coinfection is genotype-based and complex due to the interaction of both viruses. In HCV-dominant cases, direct-acting antiviral drugs and peg interferon plus ribavirin are used for the treatment, with continuous monitoring of AST and ALT. HBV-dominant cases are less common and are treated with peg interferon and nucleoside nucleotide analogues with monitoring of AST and ALT. The SVR rate in HCV-HBV coinfection is higher than that in monoinfection when treated with direct-acting antiviral drugs. But there is a risk of reactivation of HBV during and after therapy. The rate of reactivation is lower in patients treated with direct-acting antiviral drugs as compared to those treated with peg interferon plus ribavirin. Biomarkers of HBV such as HBcrAg, HBV DNA and HBVpg RNA are not effective in the prediction of HBV reactivation; only the hepatitis B surface antigen titre can be used as a biomarker for HBV reactivation. HCV can also be reactive, but this is found in very rare cases in which HBV is present and is treated first.

show abstract

Section: Global Epidemiology Of Hcv-hbv Coinfectionmentioning

confidence: 99%

Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives

Maqsood,

Sumrin,

Iqbal

et al. 2023

Antiviral Therapy

View full text Add to dashboard Cite

show abstract

“…More work from Uganda gives us a recent glimpse into the epidemiology of HIV, based on a survey and explores age, gender, number of sexual partners and frequency of testing7. And from Pakistani8, we have a report on molecular surveillance of HCV mono-infection and HCV-HBV co-infection, while Tunisian researchers highlight the burden and importance of rabies9. No doubt, a treatise on infectious diseases would be incomplete without mention of malaria and helminths.…”

mentioning

confidence: 99%

Progress in infections, reproductive health and non-communicable diseases

Tumwine¹

2018

Afr H. Sci.

View full text Add to dashboard Cite

An Integrated, Portable, and Automatic Digital Detection System for Hepatitis B Virus Using Hybrid Magnetic System

Han,

Yin,

Wang

et al. 2025

Small Methods

View full text Add to dashboard Cite

The rapid, precise, and automated diagnosis of infectious diseases is crucial for effective disease management and control. Herein, the integrated portable and automatic digital detection system (IPADS), a novel diagnostic platform for nucleic acid detection is introduced. The device employs the hybrid magnetic system (HMS), which uses an electromagnet and a movable permanent magnet to modulate the magnetic field and control bead movement, increasing nucleic acid extraction efficiency to over 80%, while simplifying the traditional labor‐intensive process and enabling quick, low‐risk sample processing. Additionally, a disposable cartridge is designed for integrated HMS based preprocessing, with detection performed using digital RPA‐Cas12a, enabling rapid, enclosed, and automation‐friendly detection across a dynamic range spanning five orders of magnitude, with a sensitivity as low as 100 copies mL−1 in serum samples. An automated platform further optimizes workflow. As a proof of concept, IPADS is applied to detect hepatitis B virus (HBV) DNA in 20 clinical serum samples, demonstrating high concordance with gold‐standard quantitative PCR (qPCR) methods. These results validate the potential of IPADS as a reliable point‐of‐care testing solution.

show abstract

Molecular surveillance of HCV mono-infection and HCV-HBV co-infection in symptomatic population at Hyderabad, Pakistan

Cited by 3 publications

References 26 publications

Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives

Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives

Progress in infections, reproductive health and non-communicable diseases

An Integrated, Portable, and Automatic Digital Detection System for Hepatitis B Virus Using Hybrid Magnetic System

Contact Info

Product

Resources

About